Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1887-1892

  Oliveras Ferraros, Cristina ^a,b   Vall Llovera, Anna Massaguer ^c   Vazquez Martin, Alejandro ^a,b   Salip, Dolors Carrion ^c   Queralt, Bernardo ^b,d   Cufí, Silvia ^a,b   Martin Castillo, Begoña ^b,e   Bosch Barrera, Joaquim ^b,d   Brunet, Joan ^b,d   De Llorens, Rafael ^c   Menendez, Javier A ^a,b  

^a Catalan Institute of Oncology ICO   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

^d Medical Oncology   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Cetuximab; EGFR; HER2; KRAS; Lapatinib; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; TRASTUZUMAB;

ACCURACY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC RESISTANCE; HER2 GENE; MOLECULAR MODEL; ONCOGENE K RAS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; TUMOR GENE; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, ERBB-2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84860730743     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1732     Document Type: Article

References (21)

1. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, et al: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86, 2011.
2. Quesnelle KM and Grandis JR: Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17: 5935-5944, 2011.
3. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al: A molecularly annotated platform of patient-derived xenografts ('xenopatients') was exploited for identifying novel mechanisms of resistance to cetuximab-resistant colorectal cancer. Cancer Discov 1: 508-523, 2011.
4. Ciardiello F and Normanno N: HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. Cancer Discov 1: 472-474, 2011.
5. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR and Salomon DS: Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog 6: 43-52, 1992.
6. Giunciuglio D, Culty M, Fassina G, Masiello L, Melchiori A, Paglialunga G, Arand G, Ciardiello F, Basolo F and Thompson EW: Invasive phenotype of MCF10A cells overexpressingc-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 63: 815-822, 1995.
7. Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S, Bianco AR and Tortora G: Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer 85: 710-715, 2000. (Pubitemid 30080486)
8. Menendez JA, Vazquez-Martin A, Oliveras-Ferraros C, Garcia-Villalba R, Carrasco-Pancorbo A, Fernandez-Gutierrez A and Segura-Carretero A: Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. Int J Oncol 34: 43-51, 2009.
9. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006. (Pubitemid 43259947)
10. Oliveras-Ferraros C, Vall-Llovera AM, Salip DC, Vazquez-Martin A, Cufí S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R and Menendez JA: Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs 30: 846-852, 2012.
11. Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J and Menendez JA: Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells. J Cell Biochem 112: 10-29, 2011.
12. Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, et al: Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol 39: 1455-1479, 2011. 1892
13. Paik S, Kim C and Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358: 1409-1411, 2008. (Pubitemid 351468442)
14. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, et al: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28: 4307-4315, 2010.
15. Arteaga CL: Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol 24: 3722-3725, 2006.
16. Menendez JA, Mehmi I and Lupu R: Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24: 3735-3746, 2006. (Pubitemid 46622312)
17. Korkaya H and Wicha MS: HER-2, notch, and breast cancer stem cells: Targeting an axis of evil. Clin Cancer Res 15: 1845-1847, 2009.
18. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S and Tagliabue E: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15: 2010-2021, 2009.
19. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA: The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 126: 355-364, 2011.
20. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10, 2007.
21. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA and Arteaga CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919, 2007. (Pubitemid 47294799)